Our board members

Professor Kevin Shakesheff (Chair)

Professor Kevin Shakesheff is Pro-Vice-Chancellor for the Faculty of Science at the University of Nottingham and Chair of the University’s Animal Welfare and Ethical Review Body. He is Professor of Advanced Drug Delivery and Tissue Engineering and Director of the UK Regenerative Medicine Platform Hub for Acellular Technologies. Kevin has published over 250 papers, focusing on regenerative medicine and applying tissue engineered models in vitro in drug discovery and safety profiling, technologies that are key to advancing the 3Rs.

Following a PhD at Nottingham, Kevin took up a NATO Postdoctoral Fellowship at MIT before returning to Nottingham in 1997. In 2001 he was appointed to a Professorship and in 2013 he became a Royal Society Wolfson Merit Award Holder. He was a Sub-Panel Member for the Research Excellence Framework (REF) for 2014. Kevin is a Fellow of the Royal Pharmaceutical Society and the Royal Society of Biologists, and in 2014 he was selected as one of the 10 most inspirational scientists in the UK by the Engineering and Physical Sciences Research Council (RISE Leader Award).

Term ends: December 2022 | Declaration of interests (PDF)

Dr Paul Brooker

Following study at the University of East Anglia and University College London, Dr Paul Brooker worked for 33 years at Envigo, Europe’s largest preclinical contract research organisation. Beginning his work in the genetic toxicology group, Paul held a number of other positions, including Director of Toxicology, before finally taking up the role of President, EMEA (Europe, Middle East and Asia Pacific). In this role he was responsible for all of the scientific and breeding operations of Envigo across its 28 EMEA sites, involving over 3,000 scientific and technical staff across a range of disciplines.
 
Paul retired from Envigo in October 2016, but has continued his involvement in the biosciences. Currently he is a Member of the Executive Committee of the British Toxicology Society; Member of Council and Treasurer of the Royal Society of Biology; and Director, Board Member and Trustee of the Science Media Centre.

Term ends: December 2020 | Declaration of interests (PDF)

Professor Chris Denning

Professor Chris Denning is Head of the Department of Stem Cell Biology at the University of Nottingham. He leads the University's Research Priority Area in Regenerative Medicine & Stem Cells. His lab's interests are in cardiomyocyte differentiation of human pluripotent stem cells, focusing on three main areas: disease modelling, including CRISPR/Cas9; platforms for cardiotoxicity and drug evaluation; and automation of stem cell culture, differentiation and screening via interdisciplinary approaches.

Chris completed his PhD in Cancer Gene Therapy at the University of Glasgow, then undertook postdoctoral research at the University of Edinburgh and the Roslin Institute before joining the University of Nottingham. He is currently Chair of the NC3Rs Development and Impact Assessment Panel, and sits on the NC3Rs' 3Rs Prize Panel. He is also a member of the Editorial Board of Stem Cell Research and Stem Cells & Development. He has received two NC3Rs Project grants and a CRACK IT Challenge grant.

Term ends: December 2020 | Declaration of interests (PDF)

Professor Paul Evans

Professor Paul Evans is Chair of Cardiovascular Science at the University of Sheffield, as well as Director of the Repair and Regeneration Research Node. His research uses a cross-disciplinary approach to study the biomechanical mechanisms that control atherosclerosis. His work has been recognised by the award of the Medawar Medal (British Transplantation Society), John French Lecture (British Atherosclerosis Society) and Michael Davies Award (British Cardiovascular Society).

Paul chairs the AWERB at the University of Sheffield and was previously Chair of the European Society for Cardiology Working Group on Atherosclerosis and Vascular Biology. He is currently a member of the MRC's Non-Clinical Fellowships Panel. He has served on the NC3Rs Project Grant and Fellowship panels and is the academic mentor to the NC3Rs Regional Programme Manager for Yorkshire and the North West.

Term ends: December 2022 | Declaration of interests (PDF)

Dr Paul Finnemore

Dr Paul Finnemore is a veterinary surgeon, with postgraduate qualifications in laboratory animal science and business administration. He is the Chief Veterinary Officer (Head of Global Animal Research Assurance) for the AstraZeneca group of companies. He has previously served as an Inspector in the Animals in Science Regulation Unit (ASRU) at the Home Office, and as the Deputy Named Veterinary Surgeon at the University of Oxford.

Paul's key areas of expertise include laboratory animal veterinary medicine, the assessment and promotion of improvement in animal care programmes, and expert knowledge of the Animals (Scientific Procedures) Act 1986 and EU Directive 2010/63/EU. He is a Council Member of the Laboratory Animals Veterinary Association, Council Member of Understanding Animal Research, and an ad-hoc consultant to AAALAC International.

Term ends: December 2020 | Declaration of interests (PDF)

Professor Paul Garside

Professor Paul Garside is a member of the Wellcome Centre for Molecular Parasitology and a Professor of Immunobiology at the University of Glasgow. The key theme of his research is investigating the fundamentals of immune regulation in vivo and applying findings to infectious and autoimmune disease scenarios. He has been awarded funding for his research from a diverse range of organisations, including the MRC, the Wellcome Trust, the Scottish Government and the European Commission. He also has ongoing collaborations with several pharmaceutical companies including Bristol-Myers Squibb, AstraZeneca and Biogen.
 
In addition to his research and teaching commitments, Paul is a lead researcher on the Malawi Healthcare Project, a joint healthcare project linking the University of Glasgow and Malawi’s College of Medicine to investigate and overcome global health challenges. He is a Fellow of the Royal Society of Biology and the Royal Society of Edinburgh and is currently Chair of the NC3Rs' PhD Studentship Assessment Panel.

Term ends: December 2020 | Declaration of interests (PDF)

Professor Christopher George

Professor Christopher George leads the Molecular Cardiology group at Swansea University Medical School, where he researches the mechanisms that underpin the predictability and variability in the response of stem-cell derived heart cell networks to genetic mutations and drugs. Through this work, Chris is developing new in silico methods for predictive toxicology. He is a Senior Editor of the British Journal of Pharmacology, with responsibility for the journal's cardiovascular portfolio. He is also a member of the editorial boards of Cardiovascular ResearchFrontiers in Physiology and Artery Research.

Chris is currently a member of the NC3Rs Grant Assessment Panel and has served as its Deputy Chair since 2018, as well as being a member of the Technologies to Tools Panel. He was previously Faculty Lead Researcher at the National Institute of Social Care and Health Research and an Executive Member of the Cardiovascular Research Group-Cymru.

Term ends: December 2022 | Declaration of interests (PDF)

Ms Linda Horan

Ms Linda Horan is Manager of the Biomedical Procedures Unit (BPU) at the University of Strathclyde. She has overall responsibility for the BPU, a large multi-discipline laboratory animal facility that supports around 80 personal licensees, providing a vital support service for research and teaching at Strathclyde. In this role she has overseen a merger of two units into one new facility, managed major refurbishment projects and controlled a budget in excess of £0.5M.

Linda has over thirty-five years’ experience in managing animal facilities. She is the current Convenor of the ScotPIL committee and has helped to deliver its accredited training courses, which have trained over one thousand Home Office personal licensees. She has held various roles within the professional body the Institute of Animal Technology (IAT) and this year became Chair/Chief Executive Officer of the IAT Council.

Term ends: December 2022 | Declaration of interests (PDF)

Dr David Lovell

Dr David Lovell is Reader in Medical Statistics and Associate Dean for Career Development of Research Staff at St George’s Medical School, University of London. His research focuses on facilitating the design, analysis and interpretation of a wide range of experimental and observational studies at St George’s. He has experience of working in both academia and industry, for organisations that include the University of Surrey, Pfizer, BIBRA and the Medical Research Council. He was also a Postdoctoral Fellow at the National Institute of Environmental Health Sciences in North Carolina USA.

David is currently Chair of the Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment and a Member of the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. He is also a member of the Editorial Boards of Biomarkers and Mutagenesis.

Term ends: December 2020 | Declaration of interests (PDF)

Dr Sally Robinson

Dr Sally Robinson is Director of Animal Sciences and Technologies at AstraZeneca (Alderley Park), where she is also the Establishment Licence Holder. A toxicologist by training, she has over 25 years of experience in the pharmaceutical industry with a focus on the application of the 3Rs. Between 2008 and 2013 she managed AstraZeneca’s Home Office Compliance Group, and between 2012 and 2013 she represented AstraZeneca on the UK Bioscience Coalition, which focused on the transposition of EU Directive 2010/63 to UK law.

Sally received the Society of Toxicology’s ‘Enhancement of Animal Welfare’ award in 2009 for leading a cross-industry NC3Rs project that led to changes in international regulatory guidance. She is currently Chair of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Research and Animal Welfare Group and a member of the UK Home Office’s Animals in Science Committee.

Term ends: December 2022 | Declaration of interests (PDF)

Professor Blanca Rodriguez

Professor Blanca Rodriguez is a Wellcome Trust Senior Research Fellow in Basic Biomedical Sciences and Professor of Computational Medicine at the University of Oxford. Her research focuses on the investigation of causes and modulators of variability in the response of the heart to disease and therapies, using computational modelling and simulation to expand and augment the information extracted from experimental and clinical methods used in cardiac electrophysiology. She is the recipient of three NC3Rs grants.

Blanca is a member of the e-cardiology Nucleus Group of the European Society of Cardiology and provides expert advice on in silico methods for toxicology and pharmacology assessment to industry and organisations such as the US Food and Drug Administration and the European Partnership for Alternative Approaches to Animal Testing. She also acts as Associate Editor of Pharmacology and Therapeutics and is a member of the Editorial Board of the open access journal PLoS ONE.

Term ends: December 2020 | Declaration of interests (PDF)

Professor Jon Timmis

Professor Jon Timmis is the Pro-Vice-Chancellor for Partnerships and Knowledge Exchange and Professor of Intelligent and Adaptive Systems in the Department of Electronic Engineering at the University of York. He is also the CEO of SimOmics Ltd, a spin-out company that provides cloud-based tools to support the 3Rs in testing, understanding toxicological risk and increased transparency of mathematical and computational models.
 
Jon's research is interdisciplinary and revolves around computational immunology and immuno-engineering, using swarm robotic systems as a platform for testing ideas relating to self-repairing autonomous systems. He leads the project team for the Maximise CRACK IT Challenge to develop an integrated web platform for agro-chemical formulation toxicity classification and data sharing.  He is a previous recipient of the Royal Society/Wolfson Research Merit Award and the Royal Academy of Engineering Enterprise Fellowship.

Term ends: December 2020 | Declaration of interests (PDF)

Professor Lucy Walker

Professor Lucy Walker is Chair of Immune Regulation at University College London's Institute of Immunity and Transplantation. She leads a research team investigating immune tolerance and autoimmunity, with a particular focus on type 1 diabetes. In September 2015 she was awarded a Royal Society Wolfson Research Merit Award. She currently holds grants from the Medical Research Council, the Horizon2020 Marie Skłodowska-Curie Innovative Training Network Programme and Diabetes UK.

Lucy is currently the Chair of the NC3Rs Training Fellowship Assessment Panel. She has also served on numerous other national and international funding committees including for the JDRF and the Wellcome Trust, and is a member of the Editorial Board for Clinical & Experimental Immunology and the Journal of Molecular Medicine. In September 2016 she was awarded the European Federation of Immunological Societies (EFIS) Lecture Award.

Term ends: December 2020 | Declaration of interests (PDF)

Dr Frances Rawle

Dr Frances Rawle represents the MRC on the NC3Rs Board.  She is Director of Policy and Governance at the MRC, a role which includes responsibility for governance and accountability for the MRC within UK Research and Innovation, and for development and implementation of policies in areas such as good research practice, research integrity, data sharing and transparency, research using personal data and research involving animals. She also has responsibility for research ethics and leads the MRC’s work aimed at improving reproducibility in biomedical research. 

Declaration of interests (PDF)

Dr Sadhana Sharma

Dr Sadhana Sharma represents the BBSRC on the NC3Rs Board. She is the Interim Head of Strategy for Bioscience for Health at the BBSRC and is responsible for leadership and coordination of this strategic area, which encompasses Lifelong Health, Nutrition for Health, One Health and Biotechnology for Health.

Declaration of interests (PDF)

Dr Vicky Robinson CBE

Dr Vicky Robinson CBE is the Chief Executive of the NC3Rs. For more information, please see her staff page.